Mark Leick (@Mark_Leick) header
Mark Leick (@Mark_Leick) profile picture

MD | Assistant Professor at HMS | MGH Bone Marrow Transplantation and Cellular Therapy | Leick Lab | @OslerHousestaff 2014-2017

Boston, MA
Joined December 2016
Photo by Mark Leick (@Mark_Leick)Photo by Mark Leick (@Mark_Leick)Photo by Mark Leick (@Mark_Leick)Photo by Mark Leick (@Mark_Leick)Photo by Mark Leick (@Mark_Leick)
Today, @NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators @MGHNeurosurg and @MGHCancerCenter! nej.md/3VnjUIq
33
176
26
826
141,010
Excited to share that @Majzner_Lab is moving to @DanaFarber @DFBC_PedCare as of Sept. Bittersweet to leave Stanford, but looking forward to growing our research program both in the lab and in the clinic. Hiring postdocs, scientists & lab manager- please reach out if interested!
38
24
8
279
56,483
🚨Next-level T cell engineering enters the clinic! DNA base editor to simultaneously silence CD7 (minimize fratricide), TCRB (minimize GVHD), and CD52 (host pre-conditioning) in allo CD7 CAR-expressing T cells for T-ALL. No DNA cuts, no translocations. nejm.org/doi/full/10.1056/NE…
43
5
161
28,741
Really happy to see the wonderful work from colleagues in Rome using 3rd gen GD2 CARs for neuroblastoma. This is the largest series of CAR T responses in a solid tumor to date & the fact that it’s in a pediatric cancer is awesome! Bravo! nejm.org/doi/full/10.1056/NE…
2
35
5
171
27,594
Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student!), this manuscript details our attempts to reimagine the structure of CARs to improve their specificity and efficacy. rdcu.be/c7avS
24
77
13
315
68,441
'Multiomics STEP up in correlative analysis of response to CAR T cells'. In this article, Mark Leick & Marcela Maus discuss the potential of cfDNA-based analyses to inform on CAR T cell expansion kinetics & tumour-infiltration patterns in patients: nature.com/articles/s41571-0…
28
1
63
9,849
We are hiring! Interested in engineering, genomics and T cell therapies for cancer? Want to work with awesome people? Looking for a great place to live? Come join us in St Louis! More info about us here: sites.wustl.edu/nathansinghl… Apply here: wustl.wd1.myworkdayjobs.com/… Please RT!
22
1
37
7,418
Great talk on germline HLH variants affecting CAR-T toxicity by @Mark_Leick @MarcelaMaus , looking forward to collaborating! #ASH22 @DrFredLocke
3
34
Hope you picked up your badge at the airport… 😬#ASH22
1
1
12
If you assumed we are talking about CAR-T, you would be correct! @jaepark @MarcelaMaus @Mark_Leick #ASH22
1
5
1
59
Thoughtful piece in @NatureMedicine from @Eddie_Cliff, Reid Merryman, Philippe Armand and Caron Jacobson @harvardmed @DanaFarber on #CARTcells in #DLBCL. Thanks for writing this! #lymphoma #lymsm
Our commentary in @NatureMedicine addresses 3 critical unanswered questions in the use of 2L CAR-T for DLBCL: 1) How to approach patients w chemo-sensitive disease? 2) Bridging therapy & 3) cost. Would love to hear your thoughts (no paywall): rdcu.be/cZfkl #lymsm
2
7
Mark Leick retweeted
SPOTLIGHT: Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell #lymphoma @Mark_Leick @SatyenGohil @gaddyg @MarcelaMaus. Originally published in @NatureMedicine. To read our summary click ow.ly/zu6N50KVJTZ and scroll all the way down.
1
3
Large propensity score matched study #axicel vs #tisacel in @NatureMedicine by @BachyEmmanuel et al Closely matched large cohorts ⬆️ ORR, CR, PFS & OS advantage for #axicel pts 1 yr OS 63.5% vs 48.8% p=0.0072 ⬆️ G1-2 CRS, & all grade ICANS in #axicel pts #CART #lymsm #DLBCL
1
23
1
79
Its finally out @NatureMedicine ! Excited to share our work identifying an association between CAR-Tregs and relapse/resistance after CAR-T cell treatment in DLBCL via scRNAseq and then modeling it in vivo (along with much more!)
[1/6 🧵] Today @NatureMedicine! Cellular dynamics monitored over time at the #SingleCell level reveals new insights into why some patients with large B cell lymphomas respond better than others to #CARTcell therapy rdcu.be/cVqVs Read the main takeaways below 👇!
2
10
50
Thrilled to kick off the 10th Annual Industrial Symposium in Montpellier with the keynote lecture this morning!
1
3
25
Incredibly honored to be recognized and supported by the Damon Runyon Cancer Research and Mark Foundations and to be blessed with such a wonderful mentor @MarcelaMaus @MGHCancerCenter
Replying to @DamonRunyon
@Mark_Leick, the @TheMarkFdn Physician-Scientist, will use genetic modifications and/or a dual targeting approach to improve CAR T cell therapy for acute myeloid leukemia.
5
2
1
50